Nykode Therapeutics AS (VACBF) Short Interest Ratio & Short Volume → The 1,000X Crypto Playbook (From True Market Insiders) (Ad) Free VACBF Stock Alerts $1.50 0.00 (0.00%) (As of 05/16/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartShort InterestStock AnalysisAnalyst ForecastsChartShort Interest Nykode Therapeutics AS Short Interest DataCurrent Short Volume1,866,300 sharesPrevious Short Volume1,748,600 sharesChange Vs. Previous Month+6.73%Dollar Volume Sold Short$2.33 millionShort Interest Ratio / Days to Cover0.0Last Record DateApril 30, 2024Today's Trading Volume0 sharesAverage Trading Volume3,500 sharesToday's Volume Vs. Average0% Short Selling Nykode Therapeutics AS ? Sign up to receive the latest short interest report for Nykode Therapeutics AS and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatVACBF Short Interest Over TimeVACBF Days to Cover Over TimeVACBF Percentage of Float Shorted Over Time Ad True Market InsidersThe 1,000X Crypto PlaybookChris Rowe has created a “Crypto Playbook” that anyone can follow… potentially turning small investments into pers#1 Crypto for 2024, completely FREE. Nykode Therapeutics AS Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20241,866,300 shares $2.33 million +6.7%N/A0 $1.25 4/15/20241,748,600 shares $2.19 million +7.7%N/A17486 $1.25 3/31/20241,623,000 shares $2.56 million -14.0%N/A16230 $1.58 3/15/20241,887,300 shares $2.98 million +77.3%N/A419.4 $1.58 2/29/20241,064,500 shares $1.68 million -9.1%N/A0 $1.58 2/15/20241,171,600 shares $1.85 million +26.3%N/A0 $1.58 1/15/2024768,100 shares $1.21 million +15.5%N/A0 $1.58 12/31/2023664,800 shares $1.05 million +12.1%N/A0 $1.58 12/15/2023593,100 shares $937,098.00 No ChangeN/A0 $1.58 11/30/2023593,100 shares $937,098.00 -30.2%N/A0 $1.58 11/15/2023849,200 shares $1.34 million -67.0%N/A0 $1.58 10/31/20232,576,500 shares $4.07 million -0.1%N/A25765 $1.58 10/15/20232,578,600 shares $5.80 million +5.3%N/A25786 $2.25 9/30/20232,448,000 shares $5.78 million +0.9%N/A0 $2.36 9/15/20232,426,800 shares $5.73 million +1.9%N/A0 $2.36 8/31/20232,382,800 shares $5.62 million No ChangeN/A0 $2.36 VACBF Short Interest - Frequently Asked Questions What is Nykode Therapeutics AS's current short interest? Short interest is the volume of Nykode Therapeutics AS shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 1,866,300 shares of VACBF short. Learn More on Nykode Therapeutics AS's current short interest. Is Nykode Therapeutics AS's short interest increasing or decreasing? Nykode Therapeutics AS saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 1,866,300 shares, an increase of 6.7% from the previous total of 1,748,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Nykode Therapeutics AS stock? Short selling VACBF is an investing strategy that aims to generate trading profit from Nykode Therapeutics AS as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Nykode Therapeutics AS? A short squeeze for Nykode Therapeutics AS occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of VACBF, which in turn drives the price of the stock up even further. How often is Nykode Therapeutics AS's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VACBF, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: 180 Life Sciences Short Squeeze Algernon Pharmaceuticals Short Squeeze Alpha Tau Medical Short Squeeze Apollomics Short Squeeze Artelo Biosciences Short Squeeze Ascentage Pharma Group International Short Squeeze Ascletis Pharma Short Squeeze Avacta Group Short Squeeze Awakn Life Sciences Short Squeeze AXIM Biotechnologies Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:VACBF) was last updated on 5/17/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubBiden Nomination CANCELED?The Freeport SocietyGold Set to EXPLODE!Gold Safe ExchangeThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm Press